Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency — Stella

Home/Vasopressin Deficiency/Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

View on ClinicalTrials.gov

Recruiting

Back to Vasopressin Deficiency trials

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Massachusetts General Hospital, Neuroendocrine Unit, Boston, Massachusetts

Key details

Phase

Early testing

Sponsor

Elizabeth Austen Lawson

Collaborators

Tonix Pharmaceuticals, Inc.

Enrollment target

~40 participants

Started

September 2025

Primary completion

June 2026

Age range

18 Years and older

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.